THEOBID Drug Patent Profile
✉ Email this page to a colleague
When do Theobid patents expire, and what generic alternatives are available?
Theobid is a drug marketed by Whitby and is included in two NDAs.
The generic ingredient in THEOBID is theophylline. There is one drug master file entry for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the theophylline profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Theobid
A generic version of THEOBID was approved as theophylline by RHODES PHARMS on September 1st, 1982.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for THEOBID?
- What are the global sales for THEOBID?
- What is Average Wholesale Price for THEOBID?
Summary for THEOBID
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 142 |
| Patent Applications: | 3,330 |
| DailyMed Link: | THEOBID at DailyMed |
US Patents and Regulatory Information for THEOBID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Whitby | THEOBID | theophylline | CAPSULE, EXTENDED RELEASE;ORAL | 085983-001 | Mar 20, 1985 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Whitby | THEOBID JR. | theophylline | CAPSULE, EXTENDED RELEASE;ORAL | 087854-001 | Mar 20, 1985 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
